VUM 02
Alternative Names: hUC MSCs; hUCT-MSC; UC MSCs; VUM-02Latest Information Update: 11 Nov 2024
At a glance
- Originator VCANBIO Cell and Gene Engineering
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Liver cirrhosis
- Phase I/II Diabetic neuropathies
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 06 Nov 2024 VCANBIO Cell and Gene Engineering plans a ESTEVS-I/II phase I/II trial for Graft versus host disease (Treatment-experienced, In adolescents, In adults, In the elderly) in China in January 2025 (IV) (NCT06677255)
- 27 Jun 2024 Phase-II clinical trials in Liver cirrhosis in China (IV) (NCT05224960)
- 29 Feb 2024 Phase-I clinical trials in Idiopathic pulmonary fibrosis in China (IV) (NCT06230822)